Iradimed (IRMD) Free Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 22.80% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -27.72% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -0.27% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 77.20% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -20.37% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.32% |
| 10 | Iradimed | 1.17 Bn | 1.11 Bn | 16.81 Mn | 86.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.70% |
| Dec 31, 2025 | 65.20% |
| Sep 30, 2025 | 18.98% |
| Jun 30, 2025 | 52.16% |
| Mar 31, 2025 | -21.77% |
| Dec 31, 2024 | -2.96% |
| Sep 30, 2024 | 9.56% |
| Jun 30, 2024 | 23.77% |
| Mar 31, 2024 | 64.55% |
| Dec 31, 2023 | 12.86% |
| Sep 30, 2023 | -0.62% |
| Jun 30, 2023 | 144.31% |
| Mar 31, 2023 | -54.65% |
| Dec 31, 2022 | -11.15% |
| Sep 30, 2022 | 4.29% |
| Jun 30, 2022 | -15.11% |
| Mar 31, 2022 | 23.77% |
| Dec 31, 2021 | -1.47% |
| Sep 30, 2021 | 76.82% |
| Jun 30, 2021 | 31.71% |
| Mar 31, 2021 | -20.00% |
| Dec 31, 2020 | 59.43% |
| Sep 30, 2020 | -12.03% |
| Jun 30, 2020 | 32.48% |
| Mar 31, 2020 | 96.39% |
| Dec 31, 2019 | 26.49% |
| Sep 30, 2019 | -3.83% |
| Jun 30, 2019 | 31.09% |
| Mar 31, 2019 | -32.62% |
| Dec 31, 2018 | 17.03% |
| Sep 30, 2018 | -38.01% |
| Jun 30, 2018 | -1.83% |
| Mar 31, 2018 | 15.95% |
| Dec 31, 2017 | 38.68% |
| Sep 30, 2017 | 35.88% |
| Jun 30, 2017 | -45.78% |
| Mar 31, 2017 | -33.95% |
| Dec 31, 2016 | 39.97% |
| Sep 30, 2016 | 223.18% |